The partnership with Unilabs, a significant player in diagnostics, to use the SOPHiA DDM Platform for HRD-status testing in solid tumors, is likely to be viewed positively by investors and the market. This collaboration not only expands SOPHiA GENETICS' operational footprint but also showcases the utility and adaptability of its platform in a real-world healthcare setting, potentially leading to increased adoption and revenue growth.